PACAP and PAC1 receptor in brain development and behavior

Neuropeptides

Volumn 47, Issue 6, 2013, Pages 421-430

  Shen, Sanbing ^a   Gehlert, Donald R ^b   Collier, David A ^c  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b ELI LILLY AND COMPANY   (United States)

^c Psychiatry DHT   (United Kingdom)

Author keywords

Autism; Brain development; Knockout; PAC1; PACAP; Schizophrenia; Stress; Transgenic; VIP

Indexed keywords

3 [2 [2 (4 METHYL 1 PIPERIDINYL)ETHYL] 1 PYRROLIDINESULFONYL]PHENOL; CLOZAPINE; DUAL SPECIFICITY PHOSPHATASE 2; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; LURASIDONE; NEUROPEPTIDE; RISPERIDONE; SYNTHETIC PEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2;

ANXIETY; AUTISM; BEHAVIOR; BRAIN DEVELOPMENT; CENTRAL NERVOUS SYSTEM; CHROMOSOME 7Q; CHROMOSOME DUPLICATION; DEPRESSION; DISEASE ASSOCIATION; GAIN OF FUNCTION MUTATION; HUMAN; HUMAN GENETICS; MENTAL DISEASE; NONHUMAN; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; STRESS; TRANSGENE; TRANSGENIC MOUSE;

ANIMALIA; MUS MUSCULUS;

AUTISM; BRAIN DEVELOPMENT; KNOCKOUT; PAC1; PACAP; SCHIZOPHRENIA; STRESS; TRANSGENIC; VIP;

AMINO ACID SEQUENCE; ANIMALS; BRAIN; GROWTH SUBSTANCES; HUMANS; MENTAL DISORDERS; MICE; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; RATS; RECEPTORS, PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE, TYPE I; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; STRESS, PHYSIOLOGICAL; VASOACTIVE INTESTINAL PEPTIDE;

EID: 84888013734     PISSN: 01434179     EISSN: 15322785     Source Type: Journal    
DOI: 10.1016/j.npep.2013.10.005     Document Type: Review

References (103)

1. Agarwal A., Halvorson L.M., Legradi G. Pituitary adenylate cyclase-activating polypeptide (PACAP) mimics neuroendocrine and behavioral manifestations of stress: evidence for PKA-mediated expression of the corticotropin-releasing hormone (CRH) gene. Brain Res. Mol. Brain Res. 2005, 138:45-57.
2. Ago Y., Hiramatsu N., Ishihama T., Hazama K., Hayata-Takano A., Shibasaki Y., Shintani N., Hashimoto H., Kawasaki T., Onoe H., Chaki S., Nakazato A., Baba A., Takuma K., Matsuda T. The selective metabotropic glutamate 2/3 receptor agonist MGS0028 reverses psychomotor abnormalities and recognition memory deficits in mice lacking the pituitary adenylate cyclase-activating polypeptide. Behav. Pharmacol. 2013, 24:74-77.
3. Asnicar M.A., Köster A., Heiman M.L., Tinsley F., Smith D.P., Galbreath E., Fox N., Ma Y.L., Blum W.F., Hsiung H.M. Vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating peptide receptor 2 deficiency in mice results in growth retardation and increased basal metabolic rate. Endocrinology 2002, 143:3994-4006.
4. Aton S.J., Colwell C.S., Harmar A.J., Waschek J., Herzog E.D. Vasoactive intestinal polypeptide mediates circadian rhythmicity and synchrony in mammalian clock neurons. Nat. Neurosci. 2005, 8:476-483.
5. Basille M., Vaudry D., Coulouarn Y., Jegou S., Lihrmann I., Fournier A., Vaudry H., Gonzalez B. Comparative distribution of pituitary adenylate cyclase-activating polypeptide (PACAP) binding sites and PACAP receptor mRNAs in the rat brain during development. J. Comp. Neurol. 2000, 425:495-509.
6. Berrettini W. Are schizophrenic and bipolar disorders related? A review of family and molecular studies. Biol. Psychiatry 2000, 48:531-538. Review.
7. Bramon E., Sham P. The common genetic liability between schizophrenia and bipolar disorder: a review. Curr. Psychiatry Rep. 2001, 3:327-332. Review.
8. Christopoulos A., Christopoulos G., Morfis M., Udawela M., Laburthe M., Couvineau A., Kuwasako K., Tilakaratne N., Sexton P.M. Novel receptor partners and function of receptor activity-modifying proteins. J. Biol. Chem. 2003, 278:3293-3297.
9. Chu A., Caldwell J.S., Chen Y.A. Identification and characterization of a small molecule antagonist of human VPAC(2) receptor. Mol. Pharmacol. 2010, 77:95-101.
10. Colwell C.S., Michel S., Itri J., Rodriguez W., Tam J., Lelievre V., Hu Z., Liu X., Waschek J.A. Disrupted circadian rhythms in VIP- and PHI-deficient mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2003, 285:R939-949.
11. Colwell C.S., Michel S., Itri J., Rodriguez W., Tam J., Lelièvre V., Hu Z., Waschek J.A. Selective deficits in the circadian light response in mice lacking PACAP. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2004, 287:R1194-1201.
12. Contestabile A., Fila T., Bartesaghi R., Ciani E. Cyclic AMP-mediated regulation of transcription factor Lot1 expression in cerebellar granule cells. J. Biol. Chem. 2005, 280:33541-33551.
13. Couvineau A., Laburthe M. VPAC receptors: structure, molecular pharmacology and interaction with accessory proteins. Br. J. Pharmacol. 2012, 166:42-50.
14. Crow T.J. Nature of the genetic contribution to psychotic illness-a continuum viewpoint. Acta Psychiatr. Scand. 1990, 81:401-408.
15. Cummings K.J., Pendlebury J.D., Sherwood N.M., Wilson R.J. Sudden neonatal death in PACAP-deficient mice is associated with reduced respiratory chemoresponse and susceptibility to apnoea. J. Physiol. 2004, 555(Pt 1):15-26.
16. Cummings K.J., Willie C., Wilson R.J. Pituitary adenylate cyclase-activating polypeptide maintains neonatal breathing but not metabolism during mild reductions in ambient temperature. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2008, 294:R956-965.
17. Daniel P.B., Kieffer T.J., Leech C.A., Habener J.F. Novel alternatively spliced exon in the extracellular ligand-binding domain of the pituitary adenylate cyclase-activating polypeptide (PACAP) type 1 receptor (PAC1R) selectively increases ligand affinity and alters signal transduction coupling during spermatogenesis. J. Biol. Chem. 2001, 276:12938-12944.
18. Dautzenberg F.M., Mevenkamp G., Wille S., Hauger R.L. N-terminal splice variants of the type I PACAP receptor: isolation, characterization and ligand binding/selectivity determinants. J. Neuroendocrinol. 1999, 11:941-949.
19. Dickson L., Aramori I., McCulloch J., Sharkey J., Finlayson K. A systematic comparison of intracellular cyclic AMP and calcium signalling highlights complexities in human VPAC/PAC receptor pharmacology. Neuropharmacology 2006, 51:1086-1098.
20. -/- mutant cerebellum. J. Mol. Neurosci. 2008, 36:38-44.
21. Faraone S.V., Skol A.D., Tsuang D.W., Young K.A., Haverstock S.L., Prabhudesai S., Mena F., Menon A.S., Leong L., Sautter F., Baldwin C., Bingham S., Weiss D., Collins J., Keith T., Vanden Eng J.L., Boehnke M., Tsuang M.T., Schellenberg G.D. Genome scan of schizophrenia families in a large Veterans Affairs Cooperative Study sample: evidence for linkage to 18p11.32 and for racial heterogeneity on chromosomes 6 and 14. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2005, 139B(1):91-100.
22. Fila T., Trazzi S., Crochemore C., Bartesaghi R., Ciani E. Lot1 is a key element of the pituitary adenylate cyclase-activating polypeptide (PACAP)/cyclic AMP pathway that negatively regulates neuronal precursor proliferation. J. Biol. Chem. 2009, 284:15325-15338.
23. Gaszner B., Kormos V., Kozicz T., Hashimoto H., Reglodi D., Helyes Z. The behavioral phenotype of pituitary adenylate-cyclase activating polypeptide-deficient mice in anxiety and depression tests is accompanied by blunted c-Fos expression in the bed nucleus of the stria terminalis, central projecting Edinger-Westphal nucleus, ventral lateral septum, and dorsal raphe nucleus. Neuroscience 2012, 202:283-299.
24. Girard B.A., Lelievre V., Braas K.M., Razinia T., Vizzard M.A., Ioffe Y., El Meskini R., Ronnett G.V., Waschek J.A., May V. Noncompensation in peptide/receptor gene expression and distinct behavioral phenotypes in VIP- and PACAP-deficient mice. J. Neurochem. 2006, 99:499-513.
25. Gourlet P., De Neef P., Cnudde J., Waelbroeck M., Robberecht P. In vitro properties of a high affinity selective antagonist of the VIP1 receptor. Peptides 1997, 18:1555-1560.
26. Gray S.L., Cummings K.J., Jirik F.R., Sherwood N.M. Targeted disruption of the pituitary adenylate cyclase-activating polypeptide gene results in early postnatal death associated with dysfunction of lipid and carbohydrate metabolism. Mol. Endocrinol. 2001, 15:1739-1747.
27. Gray S.L., Yamaguchi N., Vencová P., Sherwood N.M. Temperature-sensitive phenotype in mice lacking pituitary adenylate cyclase-activating polypeptide. Endocrinology 2002, 143:3946-3954.
28. Gressens P., Hill J.M., Gozes I., Fridkin M., Brenneman D.E. Growth factor function of vasoactive intestinal peptide in whole cultured mouse embryos. Nature 1993, 362:155-158.
29. Gressens P., Hill J.M., Paindaveine B., Gozes I., Fridkin M., Brenneman D.E. Severe microcephaly induced by blockade of vasoactive intestinal peptide function in the primitive neuroepithelium of the mouse. J. Clin. Invest. 1994, 94:2020-2027.
30. Hannibal J., Jamen F., Nielsen H.S., Journot L., Brabet P., Fahrenkrug J. Dissociation between light-induced phase shift of the circadian rhythm and clock gene expression in mice lacking the pituitary adenylate cyclase activating polypeptide type 1 receptor. J. Neurosci. 2001, 21:4883-4890.
31. Hannibal J., Brabet P., Fahrenkrug J. Mice lacking the PACAP type I receptor have impaired photic entrainment and negative masking. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2008, 295:R2050-2058.
32. Hamelink C., Tjurmina O., Damadzic R., Young W.S., Weihe E., Lee H.W., Eiden L.E. Pituitary adenylate cyclase-activating polypeptide is a sympathoadrenal neurotransmitter involved in catecholamine regulation and glucohomeostasis. Proc. Natl. Acad. Sci. USA 2002, 99:461-466.
33. Hammack S.E., Roman C.W., Lezak K.R., Kocho-Shellenberg M., Grimmig B., Falls W.A., Braas K., May V. Roles for pituitary adenylate cyclase-activating peptide (PACAP) expression and signaling in the bed nucleus of the stria terminalis (BNST) in mediating the behavioral consequences of chronic stress. J. Mol. Neurosci. 2010, 42:327-340.
34. Harikrishnan L.S., Srivastava N., Kayser L.E., Nirschl D.S., Kumaragurubaran K., Roy A., Gupta A., Karmakar S., Karatt T., Mathur A., Burford N.T., Chen J., Kong Y., Cvijic M., Cooper C.B., Poss M.A., Trainor G.L., Wong T.W. Identification and optimization of small molecule antagonists of vasoactive intestinal peptide receptor-1 (VIPR1). Bioorg. Med. Chem. Lett. 2012, 22:2287-2290.
35. Harmar A.J., Arimura A., Gozes I., Journot L., Laburthe M., Pisegna J.R., Rawlings S.R., Robberecht P., Said S.I., Sreedharan S.P., Wank S.A., Waschek J.A. International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol. Rev. 1998, 50:265-270. Review.
36. Harmar A.J., Marston H.M., Shen S., Spratt C., West K.M., Sheward W.J., Morrison C.F., Dorin J.R., Piggins H.D., Reubi J.C., Kelly J.S., Maywood E.S., Hastings M.H. The VPAC(2) receptor is essential for circadian function in the mouse suprachiasmatic nuclei. Cell 2002, 109:497-508.
37. Harmar A.J., Fahrenkrug J., Gozes I., Laburthe M., May V., Pisegna J.R., Vaudry D., Vaudry H., Waschek J.A., Said S.I. Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1. Br. J. Pharmacol. 2012, 2166:4-17.
38. Hashimoto H., Shintani N., Tanaka K., Mori W., Hirose M., Matsuda T., Sakaue M., Miyazaki J., Niwa H., Tashiro F., Yamamoto K., Koga K., Tomimoto S., Kunugi A., Suetake S., Baba A. Altered psychomotor behaviors in mice lacking pituitary adenylate cyclase-activating polypeptide (PACAP). Proc. Natl. Acad. Sci. USA 2001, 98:13355-13360.
39. Hashimoto H., Hashimoto R., Shintani N., Tanaka K., Yamamoto A., Hatanaka M., Guo X., Morita Y., Tanida M., Nagai K., Takeda M., Baba A. Depression-like behavior in the forced swimming test in PACAP-deficient mice: amelioration by the atypical antipsychotic risperidone. J. Neurochem. 2009, 110:595-602.
40. Hashimoto R., Hashimoto H., Shintani N., Chiba S., Hattori S., Okada T., Nakajima M., Tanaka K., Kawagishi N., Nemoto K., Mori T., Ohnishi T., Noguchi H., Hori H., Suzuki T., Iwata N., Ozaki N., Nakabayashi T., Saitoh O., Kosuga A., Tatsumi M., Kamijima K., Weinberger D.R., Kunugi H., Baba A. Pituitary adenylate cyclase-activating polypeptide is associated with schizophrenia. Mol. Psychiatry 2007, 12:1026-1032.
41. Hashimoto R., Hashimoto H., Shintani N., Ohi K., Hori H., Saitoh O., Kosuga A., Tatsumi M., Iwata N., Ozaki N., Kamijima K., Baba A., Takeda M., Kunugi H. Possible association between the pituitary adenylate cyclase-activating polypeptide (PACAP) gene and major depressive disorder. Neurosci. Lett. 2010, 468:300-302.
42. Hattori T., Baba K., Matsuzaki S., Honda A., Miyoshi K., Inoue K., Taniguchi M., Hashimoto H., Shintani N., Baba A., Shimizu S., Yukioka F., Kumamoto N., Yamaguchi A., Tohyama M., Katayama T. A novel DISC1-interacting partner DISC1-Binding Zinc-finger protein: implication in the modulation of DISC1-dependent neurite outgrowth. Mol. Psychiatry. 2007, 12:398-407.
43. Ishiguro H., Ohtsuki T., Okubo Y., Kurumaji A., Arinami T. Association analysis of the pituitary adenyl cyclase activating peptide gene (PACAP) on chromosome 18p11 with schizophrenia and bipolar disorders. J. Neural Transm. 2001, 108:849-854.
44. Jamen F., Persson K., Bertrand G., Rodriguez-Henche N., Puech R., Bockaert J., Ahrén B., Brabet P. PAC1 receptor-deficient mice display impaired insulinotropic response to glucose and reduced glucose tolerance. J. Clin. Invest. 2000, 105:1307-1315.
45. Journot L., Waeber C., Pantaloni C., Holsboer F., Seeburg P.H., Bockaert J., Spengler D. Differential signal transduction by six splice variants of the pituitary adenylate cyclase-activating peptide (PACAP) receptor. Biochem. Soc. Trans. 1995, 23:133-137. Review.
46. Kawaguchi C., Tanaka K., Isojima Y., Shintani N., Hashimoto H., Baba A., Nagai K. Changes in light-induced phase shift of circadian rhythm in mice lacking PACAP. Biochem. Biophys. Res. Commun. 2003, 310:169-175.
47. Koga M., Ishiguro H., Horiuchi Y., Inada T., Ujike H., Itokawa M., Otowa T., Watanabe Y., Someya T., Arinami T. Replication study of association between ADCYAP1 gene polymorphisms and schizophrenia. Psychiatr. Genet. 2010, 20:123-125.
48. Kumar S., Pioszak A., Zhang C., Swaminathan K., Xu H.E. Crystal structure of the PAC1R extracellular domain unifies a consensus fold for hormone recognition by class B G-protein coupled receptors. PLoS One 2011, 6:e19682.
49. Lang B., Song B., Davidson W., MacKenzie A., Smith N., McCaig C.D., Harmar A.J., Shen S. Expression of the human PAC1 receptor leads to dose-dependent hydrocephalus-related abnormalities in mice. J. Clin. Invest. 2006, 116:1924-1934.
50. Legradi G., Das M., Giunta B., Hirani K., Mitchell E.A., Diamond D.M. Microinfusion of pituitary adenylate cyclase-activating polypeptide into the central nucleus of amygdala of the rat produces a shift from an active to passive mode of coping in the shock-probe fear/defensive burying test. Neural Plast. 2007, 2007:79102.
51. Lelievre V., Favrais G., Abad C., Adle-Biassette H., Lu Y., Germano P.M., Cheung-Lau G., Pisegna J.R., Gressens P., Lawson G., Waschek J.A. Gastrointestinal dysfunction in mice with a targeted mutation in the gene encoding vasoactive intestinal polypeptide: a model for the study of intestinal ileus and Hirschsprung's disease. Peptides 2007, 28:1688-1699.
52. Levinson D.F., Duan J., Oh S., Wang K., Sanders A.R., Shi J., Zhang N., Mowry B.J., Olincy A., Amin F., Cloninger C.R., Silverman J.M., Buccola N.G., Byerley W.F., Black D.W., Kendler K.S., Freedman R., Dudbridge F., Pe'er I., Hakonarson H., Bergen S.E., Fanous A.H., Holmans P.A., Gejman P.V. Copy number variants in schizophrenia: confirmation of five previous findings and new evidence for 3q29 microdeletions and VIPR2 duplications. Am. J. Psychiatry 2011, 168:302-316.
53. Lim M.A., Stack C.M., Cuasay K., Stone M.M., McFarlane H.G., Waschek J.A., Hill J.M. Regardless of genotype, offspring of VIP-deficient female mice exhibit developmental delays and deficits in social behavior. Int. J. Dev. Neurosci. 2008, 26:423-434.
54. Lu N., DiCicco-Bloom E. Pituitary adenylate cyclase-activating polypeptide is an autocrine inhibitor of mitosis in cultured cortical precursor cells. Proc. Natl. Acad. Sci. USA 1997, 94:3357-3362.
55. Masuo Y., Tokito F., Matsumoto Y., Shimamoto N., Fujino M. Ontogeny of pituitary adenylate cyclase-activating polypeptide (PACAP) and its binding sites in the rat brain. Neurosci. Lett. 1994, 170:43-46.
56. McInnes L.A., Escamilla M.A., Service S.K., Reus V.I., Leon P., Silva S., Rojas E., Spesny M., Baharloo S., Blankenship K., Peterson A., Tyler D., Shimayoshi N., Shimayoshi N., Tobey C., Batki S., Vinogradov S., Meza L., Gallegos A., Fournier E., Smith L.B., Barondes S.H., Sandkuijl L.A., Freimer N.B. A complete genome screen for genes predisposing to severe bipolar disorder in two Costa Rican pedigrees. Proc. Natl. Acad. Sci. USA 1996, 93:13060-13065.
57. McInnes L.A., Service S.K., Reus V.I., Barnes G., Charlat O., Jawahar S., Lewitzky S., Yang Q., Duong Q., Spesny M., Araya C., Araya X., Gallegos A., Meza L., Molina J., Ramirez R., Mendez R., Silva S., Fournier E., Batki S.L., Mathews C.A., Neylan T., Glatt C.E., Escamilla M.A., Luo D., Gajiwala P., Song T., Crook S., Nguyen J.B., Roche E., Meyer J.M., Leon P., Sandkuijl L.A., Freimer N.B., Chen H. Fine-scale mapping of a locus for severe bipolar mood disorder on chromosome 18p11.3 in the Costa Rican population. Proc. Natl. Acad. Sci. USA 2001, 98:11485-11490.
58. Moreno D., Gourlet P., De Neef P., Cnudde J., Waelbroeck M., Robberecht P. Development of selective agonists and antagonists for the human vasoactive intestinal polypeptide VPAC(2) receptor. Peptides 2000, 21:1543-1549.
59. Moro O., Lerner E.A. Maxadilan, the vasodilator from sand flies, is a specific pituitary adenylate cyclase activating peptide type I receptor agonist. J. Biol. Chem. 1997, 272:966-970.
60. Nijmeijer J.S., Arias-Vásquez A., Rommelse N.N., Altink M.E., Anney R.J., Asherson P., Banaschewski T., Buschgens C.J., Fliers E.A., Gill M., Minderaa R.B., Poustka L., Sergeant J.A., Buitelaar J.K., Franke B., Ebstein R.P., Miranda A., Mulas F., Oades R.D., Roeyers H., Rothenberger A., Sonuga-Barke E.J., Steinhausen H.C., Faraone S.V., Hartman C.A., Hoekstra P.J. Identifying loci for the overlap between attention-deficit/hyperactivity disorder and autism spectrum disorder using a genome-wide QTL linkage approach. J. Am. Acad. Child Adolesc. Psychiatry 2010, 49:675-685.
61. Miller M., Kaufman G., Reed G., Bilenker R., Schinzel A. Familial balanced insertional translocation of chromosome 7 leading to offspring with deletion and duplication of the inserted segment, 7p15 leads to 7p21. Am. J. Med. Genet. 1979, 4:323-332.
62. Miyata A., Arimura A., Dahl R.R., Minamino N., Uehara A., Jiang L., Culler M.D., Coy D.H. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem. Biophys. Res. Commun. 1989, 164:567-574.
63. Miyata A., Jiang L., Dahl R.D., Kitada C., Kubo K., Fujino M., Minamino N., Arimura A. Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38). Biochem. Biophys. Res. Commun. 1990, 170:643-648.
64. Nicole P., Lins L., Rouyer-Fessard C., Drouot C., Fulcrand P., Thomas A., Couvineau A., Martinez J., Brasseur R., Laburthe M. Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist. Alanine scanning and molecular modeling of the peptide. J. Biol. Chem. 2000, 275:24003-24012.
65. Nicot A., Otto T., Brabet P., Dicicco-Bloom E.M. Altered social behavior in pituitary adenylate cyclase-activating polypeptide type I receptor-deficient mice. J. Neurosci. 2004, 24:8786-8795.
66. Niewiadomski P., CoÛté-Monvoisin A.C., Abad C., Ngo D., Menezes A., Waschek J.A. Mice deficient in both pituitary adenylyl cyclase-activating polypeptide and vasoactive intestinal peptide survive, but display growth retardation and sex-dependent early death. J. Mol. Neurosci. 2008, 36:200-207.
67. Norrholm S.D., Das M., Légrádi G. Behavioral effects of local microinfusion of pituitary adenylate cyclase activating polypeptide (PACAP) into the paraventricular nucleus of the hypothalamus (PVN). Regul. Pept. 2005, 128:33-41.
68. Ogawa T., Nakamachi T., Ohtaki H., Hashimoto H., Shintani S., Baba A., Watanabe J., Kikuyama S., Shioda S. Monoaminergic neuronal development is not affected in PACAP-gene-deficient mice. Regul. Pept. 2005, 126:103-108.
69. Ohtsuka M., Fukumitsu H., Furukawa S. PACAP decides neuronal laminar fate via PKA signaling in the developing cerebral cortex. Biochem. Biophys. Res. Commun. 2008, 369:1144-1149.
70. Otto C., Kovalchuk Y., Wolfer D.P., Gass P., Martin M., Zuschratter W., Gröne H.J., Kellendonk C., Tronche F., Maldonado R., Lipp H.P., Konnerth A., Schütz G. MImpairment of mossy fiber long-term potentiation and associative learning in pituitary adenylate cyclase activating polypeptide type I receptor-deficient mice. J. Neurosci. 2001, 21:5520-5527.
71. Otto C., Martin M., Wolfer D.P., Lipp H.P., Maldonado R., Schütz G. Altered emotional behavior in PACAP-type-I-receptor-deficient mice. Brain Res. Mol. Brain Res. 2001, 92:78-84.
72. Otto C., Hein L., Brede M., Jahns R., Engelhardt S., Gröne H.J., Schütz G. Pulmonary hypertension and right heart failure in pituitary adenylate cyclase-activating polypeptide type I receptor-deficient mice. Circulation 2004, 110:3245-3251.
73. Pisegna J.R, Wank S.A. Cloning and characterization of the signal transduction of four splice variants of the human pituitary adenylate cyclase activating polypeptide receptor. Evidence for dual coupling to adenylate cyclase and phospholipase C. J. Biol. Chem. 1996, 19:17267-17274.
74. Porteous D.J., Millar J.K., Brandon N.J., Sawa A. DISC1 at 10: connecting psychiatric genetics and neuroscience. Trends Mol. Med. 2011, 17:699-706.
75. Przywara D.A., Guo X., Angelilli M.L., Wakade T.D., Wakade A.R. A non-cholinergic transmitter, pituitary adenylate cyclase-activating polypeptide, utilizes a novel mechanism to evoke catecholamine secretion in rat adrenal chromaffin cells. J. Biol. Chem. 1996, 271:10545-10550.
76. Ressler K.J., Mercer K.B., Bradley B., Jovanovic T., Mahan A., Kerley K., Norrholm S.D., Kilaru V., Smith A.K., Myers A.J., Ramirez M., Engel A., Hammack S.E., Toufexis D., Braas K.M., Binder E.B., May V. Post-traumatic stress disorder is associated with PACAP and the PAC1 receptor. Nature 2011, 470:492-497.
77. Said S.I., Mutt V. Polypeptide with broad biological activity: isolation from small intestine. Science 1970, 169:1217-1218.
78. Said S.I., Mutt V. Isolation from porcine-intestinal wall of a vasoactive octacosapeptide related to secretin and to glucagon. Eur. J. Biochem. 1972, 28:199-204.
79. Salihu H.M., Boos R., Schmidt W. Antenatally detectable markers for the diagnosis of autosomally trisomic fetuses in at-risk pregnancies. Am. J. Perinatol. 1997, 14:257-261.
80. Skoglösa Y., Takei N., Lindholm D. Distribution of pituitary adenylate cyclase activating polypeptide mRNA in the developing rat brain. Brain Res. Mol. Brain Res. 1999, 65:1-13.
81. Spengler D., Waeber C., Pantaloni C., Holsboer F., Bockaert J., Seeburg P.H., Journot L. Differential signal transduction by five splice variants of the PACAP receptor. Nature 1993, 365:170-175.
82. Shen S., Spratt C., Sheward W.J., Kallo I., West K., Morrison C.F., Coen C.W., Marston H.M., Harmar A.J. Overexpression of the human VPAC2 receptor in the suprachiasmatic nucleus alters the circadian phenotype of mice. Proc. Natl. Acad. Sci. USA 2000, 97:11575-11580.
83. Shen S., Lang B., Nakamoto C., Zhang F., Pu J., Kuan S.L., Chatzi C., He S., Mackie I., Brandon N.J., Marquis K.L., Day M., Hurko O., McCaig C.D., Riedel G., St Clair D. Schizophrenia-related neural and behavioral phenotypes in transgenic mice expressing truncated Disc1. J. Neurosci. 2008, 28:10893-10904.
84. Shintani N., Tomimoto S., Hashimoto H., Kawaguchi C., Baba A. Functional roles of the neuropeptide PACAP in brain and pancreas. Life Sci. 2003, 74:337-343.
85. -/-). Ann. NY Acad. Sci. 2006, 1070:545-549.
86. Shuto Y., Uchida D., Onda H., Arimura A. Ontogeny of pituitary adenylate cyclase activating polypeptide and its receptor mRNA in the mouse brain. Regul. Pept. 1996, 67:79-83.
87. Stroth N., Eiden L.E. Stress hormone synthesis in mouse hypothalamus and adrenal gland triggered by restraint is dependent on pituitary adenylate cyclase-activating polypeptide signaling. Neuroscience 2010, 165:1025-1030.
88. Stroth N., Liu Y., Aguilera G., Eiden L.E. Pituitary adenylate cyclase-activating polypeptide controls stimulus-transcription coupling in the hypothalamic-pituitary-adrenal axis to mediate sustained hormone secretion during stress. J. Neuroendocrinol. 2011, 23:944-955.
89. Suh J., Lu N., Nicot A., Tatsuno I., DiCicco-Bloom E. PACAP is an anti-mitogenic signal in developing cerebral cortex. Nat. Neurosci. 2001 Feb, 4(2):123-124.
90. Sun C., Song D., Davis-Taber R.A., Barrett L.W., Scott V.E., Richardson P.L., Pereda-Lopez A., Uchic M.E., Solomon L.R., Lake M.R., Walter K.A., Hajduk P.J., Olejniczak E.T. Solution structure and mutational analysis of pituitary adenylate cyclase-activating polypeptide binding to the extracellular domain of PAC1-RS. Proc. Natl. Acad. Sci. USA 2007, 104:7875-7880.
91. Takeda K., Okamura T., Hasegawa T. Sibs with tetrasomy 18p born to a mother with trisomy 18p. J. Med. Genet. 1989, 26:195-197.
92. Tatsuno I., Somogyvari-Vigh A., Arimura A. Developmental changes of pituitary adenylate cyclase activating polypeptide (PACAP) and its receptor in the rat brain. Peptides 1994, 15:55-60.
93. Tajiri M., Hayata-Takano A., Seiriki K., Ogata K., Hazama K., Shintani N., Baba A., Hashimoto H. Serotonin 5-HT(7) receptor blockade reverses behavioral abnormalities in PACAP-deficient mice and receptor activation promotes neurite extension in primary embryonic hippocampal neurons: therapeutic implications for psychiatric disorders. J. Mol. Neurosci. 2012, 48:473-481.
94. Tan Y.V., Couvineau A., Murail S., Ceraudo E., Neumann J.M., Lacapere J.J., Laburthe M. Peptide agonist docking in the N-terminal ectodomain of a class II G protein-coupled receptor, the VPAC1 receptor. Photoaffinity, NMR, and molecular modeling. J. Biol. Chem. 2006, 281:12792-12798.
95. Uchida D., Tatsuno I., Tanaka T., Hirai A., Saito Y., Moro O., Tajima M. Maxadilan is a specific agonist and its deleted peptide (M65) is a specific antagonist for PACAP type 1 receptor. Ann. NY Acad. Sci. 1998, 865:253-258.
96. Vacic V., McCarthy S., Malhotra D., Murray F., Chou H.H., Peoples A., Makarov V., Yoon S., Bhandari A., Corominas R., Iakoucheva L.M., Krastoshevsky O., Krause V., Larach-Walters V., Welsh D.K., Craig D., Kelsoe J.R., Gershon E.S., Leal S.M., Dell Aquila M., Morris D.W., Gill M., Corvin A., Insel P.A., McClellan J., King M.C., Karayiorgou M., Levy D.L., DeLisi L.E., Sebat J. Duplications of the neuropeptide receptor gene VIPR2 confer significant risk for schizophrenia. Nature 2011, 471:499-503.
97. Vaudry D., Hamelink C., Damadzic R., Eskay R.L., Gonzalez B., Eiden L.E. Endogenous PACAP acts as a stress response peptide to protect cerebellar neurons from ethanol or oxidative insult. Peptides 2005, 26:2518-2524.
98. Vaudry D., Falluel-Morel A., Bourgault S., Basille M., Burel D., Wurtz O., Fournier A., Chow B.K., Hashimoto H., Galas L., Vaudry H. Pituitary adenylate cyclase-activating polypeptide and its receptors: 20years after the discovery. Pharmacol. Rev. 2009, 61:283-357.
99. Vertongen P., Schiffmann S.N., Gourlet P., Robberecht P. Autoradiographic visualization of the receptor subclasses for vasoactive intestinal polypeptide (VIP) in rat brain. Peptides 1997, 18:1547-1554.
100. Xia M., Sreedharan S.P., Bolin D.R., Gaufo G.O., Goetzl E.J. Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor. J. Pharmacol. Exp. Ther. 1997, 281:629-633.
101. Yamada K., Matsuzaki S., Hattori T., Kuwahara R., Taniguchi M., Hashimoto H., Shintani N., Baba A., Kumamoto N., Yamada K., Yoshikawa T., Katayama T., Tohyama M. Increased stathmin1 expression in the dentate gyrus of mice causes abnormal axonal arborizations. PLoS One 2010, 5(1):e8596.
102. Yan Y., Zhou X., Pan Z., Ma J., Waschek J.A., DiCicco-Bloom E. Pro- and anti-mitogenic actions of pituitary adenylate cyclase-activating polypeptide in developing cerebral cortex: potential mediation by developmental switch of PAC1 receptor mRNA isoforms. J. Neurosci. 2013, 33:3865-3878.
103. Zhou C.J., Shioda S., Shibanuma M., Nakajo S., Funahashi H., Nakai Y., Arimura A., Kikuyama S. Pituitary adenylate cyclase-activating polypeptide receptors during development: expression in the rat embryo at primitive streak stage. Neuroscience 1999, 93:375-391.